284 related articles for article (PubMed ID: 21359182)
1. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.
Xu X; Xie C; Edwards H; Zhou H; Buck SA; Ge Y
PLoS One; 2011 Feb; 6(2):e17138. PubMed ID: 21359182
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y
Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834
[TBL] [Abstract][Full Text] [Related]
3. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.
Xie C; Edwards H; Lograsso SB; Buck SA; Matherly LH; Taub JW; Ge Y
Pediatr Blood Cancer; 2012 Dec; 59(7):1245-51. PubMed ID: 22488775
[TBL] [Abstract][Full Text] [Related]
5. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
Lai TH; Ewald B; Zecevic A; Liu C; Sulda M; Papaioannou D; Garzon R; Blachly JS; Plunkett W; Sampath D
Clin Cancer Res; 2016 Jul; 22(14):3537-49. PubMed ID: 26858310
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia.
Xie C; Edwards H; Xu X; Zhou H; Buck SA; Stout ML; Yu Q; Rubnitz JE; Matherly LH; Taub JW; Ge Y
Clin Cancer Res; 2010 Nov; 16(22):5499-510. PubMed ID: 20889917
[TBL] [Abstract][Full Text] [Related]
7. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors induce proteolysis of activated CDC42-associated kinase-1 in leukemic cells.
Mahendrarajah N; Paulus R; Krämer OH
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2263-73. PubMed ID: 27576506
[TBL] [Abstract][Full Text] [Related]
9. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.
Yaseen A; Chen S; Hock S; Rosato R; Dent P; Dai Y; Grant S
Mol Pharmacol; 2012 Dec; 82(6):1030-41. PubMed ID: 22923501
[TBL] [Abstract][Full Text] [Related]
11. Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells.
Zeyen P; Zeyn Y; Herp D; Mahmoudi F; Yesiloglu TZ; Erdmann F; Schmidt M; Robaa D; Romier C; Ridinger J; Herbst-Gervasoni CJ; Christianson DW; Oehme I; Jung M; Krämer OH; Sippl W
Eur J Med Chem; 2022 Apr; 234():114272. PubMed ID: 35306288
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
Wiggers CRM; Govers AMAP; Lelieveld D; Egan DA; Zwaan CM; Sonneveld E; Coffer PJ; Bartels M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27785. PubMed ID: 31044544
[TBL] [Abstract][Full Text] [Related]
13. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
14. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
Mims A; Walker AR; Huang X; Sun J; Wang H; Santhanam R; Dorrance AM; Walker C; Hoellerbauer P; Tarighat SS; Chan KK; Klisovic RB; Perrotti D; Caligiuri MA; Byrd JC; Chen CS; James Lee L; Jacob S; Mrózek K; Bloomfield CD; Blum W; Garzon R; Schwind S; Marcucci G
Leukemia; 2013 Apr; 27(4):871-8. PubMed ID: 23178755
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma.
Kikuchi J; Wada T; Shimizu R; Izumi T; Akutsu M; Mitsunaga K; Noborio-Hatano K; Nobuyoshi M; Ozawa K; Kano Y; Furukawa Y
Blood; 2010 Jul; 116(3):406-17. PubMed ID: 20351311
[TBL] [Abstract][Full Text] [Related]
16. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.
Marlow LA; Bok I; Smallridge RC; Copland JA
Endocr Relat Cancer; 2015 Oct; 22(5):777-92. PubMed ID: 26206775
[TBL] [Abstract][Full Text] [Related]
17. A novel epigenetic drug conjugating flavonoid and HDAC inhibitor confer suppression of acute myeloid leukemogenesis.
Zhang J; Gao X; Wei M; Li Y; Yang G; Yang C; Yu L
Clin Sci (Lond); 2021 Jul; 135(14):1751-1765. PubMed ID: 34282832
[TBL] [Abstract][Full Text] [Related]
18. A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells.
Jin J; Mao S; Li F; Li X; Huang X; Yu M; Guo W; Jin J
Med Oncol; 2019 Aug; 36(9):77. PubMed ID: 31372848
[TBL] [Abstract][Full Text] [Related]
19. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
